Cancer Stem Cell News Volume 3.18 | May 14 2014

Clonal Variegation and Dynamic Competition of Leukemia-Initiating Cells in Infant Acute Lymphoblastic Leukemia with MLL Rearrangement
Through Ig/TCR rearrangement analysis of mixed lineage leukemia (MLL)-AF4+ infant acute lymphoblastic leukemia (ALL) at diagnosis and xenograft leukemias from mice transplanted with the same diagnostic samples, scientists established that MLL-AF4+ infant ALL is composed of a branching subclonal architecture already at diagnosis, frequently driven by a Ig/TCR-rearranged founder clone. [Leukemia] Abstract

The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation
Investigators defined a requirement for the previously established cancer stem cell marker aldehyde dehydrogenase in the maintenance of this drug-tolerant subpopulation. [Cancer Res] Abstract

Chloroquine Eliminates Cancer Stem Cells through Deregulation of Jak2 and DNMT1
Researchers report that chloroquine sensitizes triple negative breast cancer cells to paclitaxel through inhibition of autophagy and reduces the CD44⁺/CD24^-/low cancer stem cells population in both preclinical and clinical settings. [Stem Cells] Abstract

Anaplastic Large Cell Lymphoma-Propagating Cells Are Detectable by Side Population Analysis and Possess an Expression Profile Reflective of a Primitive Origin
Researchers showed that a small subset of cells purified from human anaplastic lymphoma kinase-positive and -negative, anaplastic large cell lymphoma cell lines and primary patient tumors using the side population technique have serial tumor-propagating capacity both in vitro and in vivo. [Oncogene] Abstract

Combined PDK1 and CHK1 Inhibition Is Required to Kill Glioblastoma Stem-Like Cells In Vitro and In Vivo
In order to decode the signal transduction networks responsible for the malignant properties of glioblastoma stem-like cells (GSCs), scientists analyzed a collection of GSC lines using a dual, but complementary, experimental approach, that is, reverse-phase protein microarrays and kinase inhibitor library screening. [Cell Death Dis] Full Article

The Role of Src Family Kinases in Growth and Migration of Glioma Stem Cells
Scientists examined the expression pattern of individual members of Src family kinases and their functional role in CD133+ glioma stem cells in comparison to primary glioma cells. [Int J Oncol] Abstract

Honokiol Suppresses Renal Cancer Cells’ Metastasis via Dual-Blocking Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties through Modulating miR-141/ZEB2 Signaling
Researchers found that honokiol suppressed renal cancer cells’ metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties. [Mol Cells] Abstract | Full Article

Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells
The authors summarize the mechanisms underlying cancer stem cells (CSC) resistance, the potential biological targets to overcome resistance and the chemical compounds showing activity against different types of CSC. [Drug Discov Today] Abstract

Cancer Stem Cells: Biological Functions and Therapeutically Targeting
The authors discuss insights into cancer stem cells historical background and to provide a brief review of the new therapeutic strategies for targeting cancer stem cells. [Int J Mol Sci] Abstract | Download Full Article

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Investigating the Role of Aging and Poor Nutrition on Colon Cancer: NIH Awards Einstein $3.2 Million Grant
Researchers have received a $3.2 million grant from the National Institutes of Health (NIH) to investigate how aging and poor nutrition interact to cause the mutations responsible for driving colon cancer development. [Albert Einstein College of Medicine of Yeshiva University] Press Release

MedImmune and Incyte Announce Collaboration on Immuno-Oncology Combination Clinical Trial
AstraZeneca announced that MedImmune has entered into a clinical study collaboration with biopharmaceutical company Incyte Corporation. The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte’s oral indoleamine dioxygenase-1 inhibitor, INCB24360. [MedImmune, LLC] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cancer stem cell community.

Postdoctoral Position – Stem Cell Biology/Cancer Biology (Oregon Health and Science University)

Postdoctoral Researcher – Cancer Genomics (University of Chicago)

Postdoctoral Fellow – Cancer Development and Stem Cells (University of Texas MD Anderson Cancer Center)

Postdoctoral Position – Cancer Stem Cells (Queen Mary University of London)

Postdoctoral Fellow – Cancer Biology (University of Cincinnati)

Faculty Position – Cell, Developmental and Cancer Biology (Oregon Health & Science University)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center [DKFZ])

Faculty Positions – Cancer Research (Stephenson Cancer Center at the University of Oklahoma)

Postdoctoral Position – Cancer Biology (IRCAN)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Research Technologist – hPSC (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.